(Q40131054)

17 September 2017

1 reference

title

Cyclosporin A--usefulness, risks and mechanism of action (English)

1 reference

17 September 2017

Cyclosporin A - Usefulness, Risks and Mechanism of Action (English)

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

17 September 2023

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

17 September 2023

author name string

S. Britton

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6288546

17 September 2023

R. Palacios

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6288546

17 September 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6288546

17 September 2023

publication date

1 January 1982

1 reference

full work available at URL

17 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-065X.1982.tb00425.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-065X.1982.tb00425.x/fullpdf

17 September 2023

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

17 September 2023

published in

Immunological Reviews

1 reference

17 September 2017

65

1 reference

17 September 2017

5-22

1 reference

Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein–Barr virus-induced B-cell lines

17 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Biological effects of cyclosporin A: A new antilymphocytic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Cyclosporin A in patients receiving renal allografts from cadaver donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Oropharyngeal Excretion of Epstein-Barr Virus by Patients with Lymphoproliferative Disorders and by Recipients of Renal Homografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Risk of cancer in renal-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Cyclosporin A immunosuppression, Epstein-Barr antibody, and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

HLA-restricted T-cell recognition of Epstein–Barr virus-infected B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Endogenous Reactivation of Epstein-Barr Virus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Histocompatibility antigens controlled by the I region of the murine H-2 complex. II. K/D region compatibility is not required for I-region cell-mediated lymphocytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Characteristics of calcium accumulation by lymphocytes and alterations in the process induced by phytohemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Effect of cyclosporin A on T-dependent and T-independent immunoglobulin synthesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Cyclosporin A blocks receptors for HLA-DR antigens on T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

T-cell mitogens cause early changes in cytoplasmic free Ca2+ and membrane potential in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Nephrotoxicity of cyclosporin A in bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug-resistant cytotoxic lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Serum levels of cyclosporin A and nephrotoxicity in bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Immunological and pharmacological monitoring in the clinical use of cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Two distinct factors are required for induction of T-cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.1982.TB00425.X

A New Approach to the Study of Human B Lymphocyte Function Using an Indirect Plaque Assay and a Direct B Cell Activator

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2

17 September 2023

9

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Immunosuppression for Organ Grafting Observations on Cyclosporin A

17 September 2023

10

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Cyclosporin A in cadaveric organ transplantation

17 September 2023

11

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?

17 September 2023

13

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Studies on long-term T-cell-mediated immunity to epstein-barr virus in immunosuppressed renal allograft recipients

17 September 2023

15

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

A radioimmunoassay to measure cyclosporin A in plasma and serum samples

17 September 2023

17

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Occurrence of malignancy in immunodeficiency diseases. A literature review

17 September 2023

19

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs

17 September 2023

28

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution

17 September 2023

29

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Monoclonal Antibodies Defining Distinctive Human T Cell Surface Antigens

17 September 2023

31

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Cyclosporin a permits the distinction between specific T and NK activity generated in a human MLC

17 September 2023

32

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Interleukin 1 and T cell activation

17 September 2023

37

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

17 September 2023

39

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

HLA-DR antigens render interleukin-2-producer T lymphocytes sensitive to interleukin-1

17 September 2023

43

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Mechanism of T cell activation: role and functional relationship of HLA-DR antigens and interleukins

17 September 2023

44

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Biochimica et Biophysica Acta

17 September 2023

48

61

1180

Parker C. W.

1974

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Drug-induced Immunological Tolerance

17 September 2023

52

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

17 September 2023

T-cell growth factor

53

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

Liver transplantation with use of cyclosporin a and prednisone

17 September 2023

54

1 reference

https://api.crossref.org/works/10.1111/J.1600-065X.1982.TB00425.X

17 September 2023

Identifiers

1 reference

17 September 2017

1 reference